All In Biotech

NDA 203858 · Chiesi

Juxtapid

Lomitapide Mesylate · Oral

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Feb 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Dec 21, 2012

Approved uses

2

Original approval plus efficacy supplements

Registered trials

16

5 Phase 3, 0 recruiting

FAERS reports

3,782

1,231 serious, 94 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF HEPATOTOXICITY JUXTAPID can cause elevations in transaminases. In the adult clinical trial, 10 (34%) of the 29 patients treated with JUXTAPID had at least one elevation in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 times the upper limit of normal (ULN). There were no concomitant clinically meaningful elevations of total bilirubin, international normalized ratio (INR), or alkaline phosphatase. In the pediatric clinical trial (5 to 17 years of age), 6 (14%) of the 43 patients experienced elevations in ALT and/or AST ≥ 3 times ULN. No concomitant clinically meaningful elevations in total bilirubin or alkaline phosphatase were observed [see Warnings and Precautions (5.1) ]. JUXTAPID also increases hepatic fat, with or without concomitant increases in transaminases. The median absolute increase in hepatic fat in adult patients was 6% after both 26...

What it is approved for

From the label in effect Mar 30, 2026.

JUXTAPID is indicated as an adjunct to a low-fat diet and exercise and other low density lipoprotein cholesterol (LDL-C) therapies to reduce LDL-C in adults and pediatric patients aged 2 years and older with homozygous familial hypercholesterolemia (HoFH). JUXTAPID is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and exercise and other low-density lipoprotein cholesterol (LDL-C) therapies, to reduce LDL-C in adult and pediatric patients aged 2 years and older with HoFH. ( 1 ).

Mechanism: JUXTAPID directly binds and inhibits microsomal triglyceride transfer protein (MTP), which resides in the lumen of the endoplasmic reticulum, thereby preventing the assembly of apo B-containing lipoproteins in enterocytes and hepatocytes. This inhibits the synthesis of chylomicrons and VLDL. The inhibition of the synthesis of VLDL leads to reduced levels of plasma LDL-C.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 25, 2026 Supplement 27 · Efficacy · priority review OrphanLabelLetter
  • Dec 21, 2012 Original approval · Type 1 - New Molecular Entity NovelOrphanOtherLabelReview
7 products under this application
  • JUXTAPID · LOMITAPIDE MESYLATE EQ 2MG BASE · CAPSULE, ORAL · Prescription
  • JUXTAPID · LOMITAPIDE MESYLATE EQ 40MG BASE · CAPSULE, ORAL · Discontinued
  • JUXTAPID · LOMITAPIDE MESYLATE EQ 20MG BASE · CAPSULE, ORAL · Prescription
  • JUXTAPID · LOMITAPIDE MESYLATE EQ 5MG BASE · CAPSULE, ORAL · Prescription
  • JUXTAPID · LOMITAPIDE MESYLATE EQ 60MG BASE · CAPSULE, ORAL · Discontinued
  • JUXTAPID · LOMITAPIDE MESYLATE EQ 30MG BASE · CAPSULE, ORAL · Prescription
  • JUXTAPID · LOMITAPIDE MESYLATE EQ 10MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Lomitapide" as an intervention, any sponsor and status, largest first.

All 16 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea1,076
  • weight decreased844
  • therapy cessation792
  • nausea558
  • abdominal pain upper287
  • abdominal discomfort242
  • flatulence242
  • vomiting219
  • off label use208
  • fatigue206
  • hepatic enzyme increased188
  • drug dose omission184

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201386
2014551
20151,346
2016316
2017327
2018343
2019169
2020193
2021137
202278
202376
202464
202561
202635

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Juxtapid (Lomitapide Mesylate)

2024 spending

$7.0M

Beneficiaries

12

117 claims

Per beneficiary

$582,680

$1,968.68 per unit

View as table
YearSpending
2020$10,792,514
2021$9,434,150
2022$8,527,542
2023$8,683,000
2024$6,992,162

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 19 on PubMed

Sponsor: Chiesi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.